Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx, Inc. announced that its innovative therapy, tenapanor, has been named a finalist in the Fierce Innovation Awards for biotech innovation. This first-in-class treatment, aimed at controlling serum phosphorus levels in chronic kidney disease patients on dialysis, is backed by three successful Phase 3 studies. The awards recognize effectiveness and innovation, as reviewed by industry experts. Ardelyx submitted an NDA for tenapanor to the FDA on June 30, 2020, addressing a significant unmet need among dialysis patients, with a substantial risk of cardiovascular issues and mortality.